The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.
CMP-001 has a new name and new trial in refractory stage 4 pd-1 patients
Very interesting!!! Fingers and toes crossed for good results!
If you haven’t heard about TLR (toll like receptor) agonists, they have been used in the form of SD101 and IMO-2125 (tilsotolimod) as intralesional therapy combined with systemic immunotherapy for folks with melanoma. The later combined with yervoy is addressed at point #2, with links to previous reports and background info within, in this post if you are interested: https://chaoticallypreciselifeloveandmelanoma.blogspot.com/search?q=tlr+agonist
Hopefully, in an intravenous form, TLR’s will bring new treatment options to melanoma peeps! Thanks, Edster! – c
Thanks for posting. It does one good to know that there’s always “something” coming down the line.
Viewing 1 reply thread
You must be logged in to reply to this topic.
About the MRF Patient Forum
The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.
The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.